AIG 01012
Alternative Names: AIG-01012Latest Information Update: 12 Jul 2024
At a glance
- Originator AIGEN Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer